eylea competit concern decreas beovu
nv safeti issu upgrad buy pt
american societi retin specialist asr warn member
potenti vision loss beovu patient
asr warn case vascul case occlus retin
vascul patient receiv novarti beovu expect less usag go
forward less competit regn eylea importantli occlus retin
vascul lead perman vision loss novarti brought extern safeti
review committe evalu case compani clinic develop
pharmacovigil team attempt analyz event identifi potenti
risk factor retin vascul thu far sinc approv octob beovu
administ time accord novarti gener
expect rate administr slow physician reassess usag
eylea like maintain strong presenc wet space
competitor setback
setback nv beovu like solidifi eylea market posit near-
term lack clariti resolut novarti part could lead long-
term boon eylea adjust model incorpor stabl moder
growth outlook eylea near-term long-term wet space
expect beovu less competit go forward cours addit vigil
need see outcom novarti investig occlus retin
vascul suspect issu could remain overhang physician
eylea still model competit year lesser degre
forecast market share wet space declin less significantli
fda warn beovu may follow shortli
fda may comment case ocular vascul believ addit
warn could ad beovu product label slow uptak physician
fda add warn addit novarti may send letter
physician detail safeti find investig complet
remind drug manufactur must promptli report advers seriou advers
upgrad buy hold rais pt
believ competit risk eylea beovu decreas thu
upgrad rate buy hold increas pt
current trade consensu ep think higher
multipl warrant sinc competit overhang lift current util
multipl closer averag larg biotech/pharma continu expect
stronger growth dupix libtayo eylea diabet indic
also encourag potenti sanofi agreement restructur could give
wholli own product increas oper margin
hold
price close busi februari
biotech
discov invent manufactur
commerci medicin treat seriou
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object
view compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
buy hold target price februari
buy hold target price februari
may dataphas data osteoarthr pain knee hipinterim phase datainterim analysi os nsclc monotherapyphas datapivot phase data patientsphas data r/r data potenti phase data potenti phase data r/r b-cell malignanciesfda decis sbla expand ad indic pediatr patient year phase dataphas studi asthma pediatr patient year old phase dataphas portion data eosinophil esophag patient regeneron pharmaceut
buy hold target price februari
buy hold target price februari
fy producteyleau ex-u arcalystu ex-u revenues- libtay ex-u net product sale book praluentu ex-u ww zaltrapex-u us ww kevzarau ex-u dupixentu ex-u regeneron pharmaceut
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may
obtain contact canaccord genuiti sale person author analyst whose contact inform appear front page report
buy hold target price februari
fy bayer collabor technolog net product contract research other- total good option expensegross oper expensesresearch reimburs sanofi bayer teva option non-reimburs sell gener option expens sg ex-opt collabor total oper profit loss oper profit loss incom expens incom expens loss earli extinguish debtpre-tax incom pre-tax incom tax rate tax expens benefit tax rate tax expens benefit net incom loss adjust net net incom loss ep fulli ep fulli figur balanc sheet
buy hold target price februari
fy balanc sheetasset cash equival market secur account receiv trade account receiv sanofi account receiv bayer defer tax assets- prepaid expens current asset total current asset restrict cash market secur market secur properti plant equip cost net accumul defer tax asset total asset liabil account payabl accru expens defer revenu sanofi current portion defer revenu current portion facil leas oblig current portion current liabilities- total current liabil facil leas oblig defer revenu sanofi defer revenu long term liabil total liabil commit conting total stockhold equiti total liabil stockhold equiti figur
buy hold target price februari
fy statement flow net incom adj reconcil net loss net cash use provid oper activities- depreci non-cash compens non-cash interest expense- loss earli extinguish debt- net realiz loss gain market securities- non-cash charg expens defer chang asset liabil decreas increas account increas increas decreas prepaid expens decreas increas defer increas account payabl accru expens total flow purchas market sale matur market purchas restrict market securities- decreas increas restrict cash- capit increas restrict cash- other- flow repurchas repay note payable- proce connect facil leas obligations- payment connect facil leas obligations- net proce issuanc common payment common stock tender employe tax payment connect reduct outstand warrants- net proce issuanc convert debt- proce connect issuanc warrants- payment connect capit leas obligations- payment connect convert debt- payment connect purchas convert note hedges- excess tax benefit stock-bas compensation- repurchas common flow net increas cash cash cash equival begin cash equival end regeneron
